Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus
Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus (T2DM).
“Bringing Ozempic to India is a major milestone,” said Vikrant Shrotriya – Managing Director, Novo Nordisk India. “Backed by global trust, proven clinical excellence & world class quality, reinforced by a robust supply chain, Ozempic® offers Indian doctors an effective treatment choice. Our goal is to provide patients an innovative & accessible therapy that offers improved glycaemic control, meaningful weight management and long-term heart and kidney protection – all delivered through a simple, easy-to-use pen device. This once-weekly treatment demonstrates Novo Nordisk’s ongoing commitment to better health outcomes and chronic disease care.”
